
==== Front
MoleculesMoleculesmoleculesMolecules1420-3049MDPI 10.3390/molecules21081072molecules-21-01072ArticleSynthesis and Antimicrobial Activity of Some New Thiadiazoles, Thioamides, 5-Arylazothiazoles and Pyrimido[4,5-d][1,2,4]triazolo[4,3-a]pyrimidines Abdelhamid Abdou O. 1*El Sayed Ibrahim E. 2Hussein Mohamed Z. 3Mangoud Mangoud M. 3Bunce Richard A. Academic Editor1 Department of Chemistry, Faculty of Science, Cairo University, Giza 12613, Egypt2 Department of Chemistry, Faculty of Science, El Menoufia University, Shebin El Koom 32511, Egypt; ibrahimtantawy@yahoo.co.uk3 Environmental Research Department, National Center for Social and Criminological Research, Ibn Khaldoun Square, Mohandesin, Zamalek, Giza 11561, Egypt; mohamedzaki1955@yahoo.com (M.Z.H.); mangoud_online@yahoo.com (M.M.M.)* Correspondence: Abdelhamid45@gmail.com; Tel.: +20-0100-5205-75017 8 2016 8 2016 21 8 107225 6 2016 10 8 2016 © 2016 by the authors.2016Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).A novel series of 1,3,4-thiadiazoles, 5-arylazothiazoles and hexahydropyrimido-[4,5-d][1,2,4]triazolo[4,3-a]pyrimidines were synthesized via reaction of hydrazonoyl halides with each of alkyl carbothioates, carbothioamides and 7-thioxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidine-2,4(1H,3H)-diones in the presence of triethylamine. The structures of the newly synthesized compounds were established based on their spectral data, elemental analyses and alternative synthetic routes whenever possible. Also, the newly synthesized compounds were screened for their antimicrobial activity against various microorganisms.

hydrazonoyl halidesthioamides1,3,4-thiadiazolesthiazolespyrimido[4,5-d][1,2,4]triazolo[4,3-a]pyrimidinesantimicrobials
==== Body
1. Introduction
Hydrazonoyl halides have been widely used as reagents for the synthesis of heterocyclic compounds, both through condensation reactions, and as precursors of nitrilimines, which can undergo cycloaddition with dipolarophiles [1,2]. 1,3,4-Thiadiazoles are among the most common heterocyclic pharmacophores. They display a broad spectrum of biological activities, including antimicrobial [3] anticancer [4,5], antioxidant [6], antidepressant [7], anticonvulsant [8,9], and antihypertensive activity [10] as well as acetylcholinesterase inhibition for the treatment of Alzheimer disease [11,12]. In addition, thiazoles can found in drugs developed for the treatment of allergies [13], hypertension [14], inflammation [15], schizophrenia [16], bacterial infections [17], HIV [18], sleep disorders [19] and more recently, for the treatment of pain [20], as fibrinogen receptor antagonists with antithrombotic activity [21], and as new inhibitors of bacterial DNA gyrase B [22]. 1,2,4-Triazolopyrimidines have also attracted growing interest due to their important pharmacological activities, such as antitumor, antimalarial, antimicrobial, anti-inflammatory, antifungal properties, and their potency in macrophage activation [23,24,25,26,27].

2. Results and Discussion
Treatment of methyl 2-methylenehydrazinecarbodithioates 3a and [28] 4a with ethyl 2-chloro-2-(2-phenylhydrazono)acetate (5a) in ethanol containing triethylamine gave ethyl 5-({[1H-pyrazol-4-yl]methylene}hydrazono)-1,3,4-thiadiazole-2-caboxylates 9a and 10a, respectively (Scheme 1). The structure 9a was established by elemental analysis, 1H-NMR, IR spectroscopy, mass spectrometry and alternative syntheses. Thus, (5E)-ethyl 5-hydrazono-4,5-dihydro-4-phenyl-1,3,4-thiadiazole-2-carboxylate [29] (11) was reacted with 1a and 1b to give products identical in all aspects (m.p., mixed m.p. and spectra) with 9a and 10a, respectively. In addition, benzyl 2-((1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)-methylene)-hydrazine-1-carbodithioate (3b) was reacted with 5a in ethanolic triethylamine to give a product identical in all aspects (m.p., mixed m.p. and spectra) with 9a. In light of the foregoing results, the mechanism outlined in Scheme 1 seems to be the most plausible pathway for the formation of 9 from the reaction of the 5 with 3a or 3b. The reaction involves initial formation of thiohydrazonate 7, which undergoes intermolecular cyclization directly to yield intermediate 8 or via 1,3-dipolar cycloaddition of nitrilimine 6 (generated in situ from 5 with triethylamine) to the C=S of 3 or 4 to yield intermediate 8. Formations of 7 and 8 are similar to the reaction of hydrazonoyl chloride with 1-phenyl-1,4-dihydrotetrazole-5-thione [30] and 5-phenyl-1,3,4-thiadiazole-2(3H)-thione [31]. Intermediate 8 was converted to 9 by elimination of alkyl mercaptan. Analogously, 5b, 5c were reacted separately with 3a, 3b, 4a or 4b in ethanolic triethyamine to afford 2,3-dihydro-1,3,4-thiadiazoles 9b–c and 10a–c, respectively (Scheme 1).

Treatment of 3-(furan-2-yl)-1-(p-tolyl)prop-2-en-1-one (12a), 1-(furan-2-yl)-3-(3-(furan-2-yl)-1-phenyl-1H-pyrazol-4-yl)prop-2-en-1-one (12b), 3-(3-(furan-2-yl)-1-phenyl-1H-pyrazol-4-yl)-1-(p-tolyl)prop-2-en-1-one (12c), 3-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)-1-(p-tolyl)prop-2-en-1-one (12d), 1,3-di(furan-2-yl)prop-2-en-1-one (12e) and 1-(furan-2-yl)-3-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)-prop-2-en-1-one (12f) with thiosemicarbazide in boiling ethanol containing potassium hydroxide gave 5-(furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (13a), 3’,5-di(furan-2-yl)-1’-phenyl-3,4-dihydro-1’H,2H-[3,4’-bipyrazole]-2-carbothioamide (13b), 3’-(furan-2-yl)-1’-phenyl-5-(p-tolyl)-3,4-dihydro-1’H,2H-[3,4’-bipyrazole]-2-carbothioamide (13c), 1’-phenyl-3’,5-di-p-tolyl-3,4-dihydro-1’H,2H-[3,4’-bipyrazole]-2-carbothioamide (13d), 3,5-di(furan-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (13e) and 5-(furan-2-yl)-1’-phenyl-3’-(p-tolyl)-3,4-dihydro-1’H,2H-[3,4’-bipyrazole]-2-carbothioamide (13f), respectively (Scheme 2).

Thus, thioamide 13a was reacted with the hydrazonoyl halides 5b and 5c in boiling ethanol containing triethylamine to give 2-(5-(furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-methyl-5-(phenyldiazenyl)thiazole (14a) and 2-(5-(furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenyl-5-(phenyldiazenyl)thiazole (15a), respectively (Scheme 3). Thus, benzenediazonium chloride was reacted with 2-(5-(furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenyl-thiazole (16), which was prepared via the reaction of 12a with 2-hydrazinyl-4-phenylthiazole [32] (17) or the reaction of compound 13a with ω-bromoacetophenone in pyridine at 0–5 °C to give a product identical in all aspects (mp., mixed mp. and spectra) with 15a (Scheme 3).

Analogously, treatment of the appropriate 13b–f with the hydrazonoyl halides 5b and 5c in boiling ethanol containing triethylamine afforded 2-substituted-4,5-dihydro-1H-pyrazol-1-yl)-4-subsituted-5-(phenyldiazenyl)thiazoles 14b–f and 15b–f, respectively (Scheme 4).

On the other hand, treatment of ethyl 2-chloro-2-(2-phenylhydrazono)acetate (5a) with 5-(furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (13a), in boiling ethanol containing triethylamine gave one isolable product according to TLC and proved to be 2-(5-(furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-5-(2-phenylhydrazono)thiazol-4(5H)-one (18a). Also, benzenediazonium was reacted with 2-(5-(furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-5(4H)-one (19), which was prepared via the reaction of ethyl chloroacetate with 13a, in ethanolic sodium acetate solution at 0–5 °C to afford a product identical in all aspects (mp, mixed mp and spectra) with 18a (Scheme 5)

Similarly, carbothioamides 13b–d, and 13f were reacted with C-ethoxycarbonyl-N-phenylhydrazonyl chloride in ethanolic triethylamine to give the corresponding thiazolone derivatives 18b–e, respectively (Scheme 6).

In further experiments treatment of 5a with 5,6,7,8-tetrahydro-1,3-dimethyl-5-(1-phenyl-3-p-tolyl-1H-pyrazol-4-yl)-7-thioxopyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione 20 in boiling chloroform containing triethylamine produced ethyl 2,4-dioxo-1,2,3,4,5,7-hexahydro-pyrimido[5,4-e]-[1,2,4]-triazolo[4,3-a]pyrimidine-9-carboxylate 26a in good yields (Scheme 7).

The 1H-NMR spectrum of 26a showed a triplet at δ 1.18 due to methyl group of ethyl ester, a singlet at δ 2.33 of tolyl methyl group, a singlet at δ 3.33 from the two pyrimidinedione methyl groups, a quartet at δ 4.13 due to the methylene of ethyl ester, a singlet at δ 5.62 that corresponding to the pyrimidine H-4 and a multiplet at δ 6.90–7.83 that account for 14 aromatic protons and H-5 of pyrazole. In the IR spectrum, an absorption peak at 1650 cm−1 corresponding to conjugated carbonyl groups and an absorption near at 1615 cm−1 could account for the presence of the imino group.

The mechanism outlined in scheme 7 seems to be the most plausible pathway for the formation of 26a from the reaction of 5 with 20: (1) 1,3-addition of the thiol tautomer 21 to the nitrilimine 6a would give the thiohydrazonate ester 22 which could undergo nucleophilic cyclization to yield spiro compounds 23. The latter ring could then open and cyclize to yield 26a with loss of hydrogen sulfide; and (2) 1,3-cycloaddition of nitrilimine 6a to C=S of 20 would directly yield 22 (cf., Scheme 7). Attempts to isolate the thiohydrazonate ester 22 or intermediates 23 and 24 did not succeed even under mild conditions as they readily undergo in situ cyclization followed by elimination of hydrogen sulfide to give the final product 26 in Scheme 7.

Analogously, reaction of 20 with each of 5b and 5d afforded 3-acetyl-7,9-dimethyl-1-phenyl-5-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)-5,9-dihydropyrimido[4,5-d][1,2,4]triazolo[4,3-a]pyrimidine-6,8(1H,7H)-dione (26b) and 7,9-dimethyl-6,8-dioxo-N,1-diphenyl-5-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)-1,5,6,7,8,9-hexahydropyrimido[4,5-d][1,2,4]triazolo[4,3-a]pyrimidine-3-carboxamide (26c), respectively. Based on the above results, structure 25 was ruled out. This structural assignment was also consistent with literature reports which indicated that reaction of hydrazonoyl halides with 2-thioxopyrimidin-4-one yielded regioselectively the corresponding 1,2,4-triazolo[4,3-a]pyrimidin-5-one derivatives [33]. Additionally, treatment of 5-(3-(furan-2-yl)-1-phenyl-1H-pyrazol-4-yl)-1,3-dimethyl-7-thioxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (27) with the hydrazonoyl chlorides 5a and 5d in boiling chloroform in the presence of triethylamine afforded ethyl 5-(3-(furan-2-yl)-1-phenyl-1H-pyrazol-4-yl)-1,3-dimethyl-2,4-dioxo-7-phenyl-1,2,3,4,5,7-hexahydro-pyrimido[5,4-e][1,2,4]triazolo[4,3-a]pyrimidine-9-carboxylate (28a) and 5-(3-(furan-2-yl)-1-phenyl-1H-pyrazol-4-yl)-1,3-dimethyl-2,4-dioxo-N,7-diphenyl-1,2,3,4,5,7-hexahydro-pyrimido[5,4-e][1,2,4]-triazol[4,3-a]pyrimidine-9-carboxamide (28b), respectively (Scheme 8).

3. Antimicrobial Activity
Twenty seven of the newly synthesized target compounds were evaluated for their in vitro antibacterial activity against Staphylococcus
aureus and Bacillus subtilis as examples of Gram-positive bacteria and Pseudomonas aeruginosa and Escherichia coli as examples of Gram-negative bacteria. They were also evaluated for their in vitro antifungal activity against a representative panel of fungal strains i.e., Aspergillus fumigatus, and Candida albicans. Ampicillin, Gentamicin and Amphotericin B are used as reference drugs for in vitro antibacterial activity and for in vitro antifungal activity, respectively, at The Regional Center for Mycology and Biotechnology at Al-Azhar University (Nasr City, Cairo, Egypt). The results of testing for antimicrobial effects are summarized in Table 1, Table 2 and Table 3.

Compound 9a had no activity against Aspergillus fumigates, Candida albicans, Streptococcus pneumonia, Bacillus subtilis, Pseudomonas aeruginosa, and Escherichia coli.

Candida albicans and Pseudomonas aeruginosa were resistant to compounds 9a, 9b, 9c, 9d, 10a, 10b, 10c, 10d, and 14f.

Aspergillus fumigatus was susceptible to compounds 13b, 14b, 15b, and 15c when compared to the Amphotericin B standard.

Candida albicans was susceptible to compound 13b when compared to the Amphotericin B standard.

Streptococcus pneumoniae was susceptible to compounds 13b, and 14b when compared to the Ampicillin standard.

Bacillus subtilis was susceptible to compounds 13b, 14b, and 15b when compared to the Ampicillin standard.

Pseudomonas aeruginosa was susceptible to compounds 13b, 15a, and 26d when compared to their standard Gentamicin.

Escherichia coli was susceptible to compounds 10a, 13b, 14b, 15f, and 28a when compared to the Gentamicin standard.

The minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight incubation. Minimum inhibitory concentrations are important in diagnostic laboratories to confirm resistance of microorganisms to an antimicrobial agent and also to determine the potency of new antimicrobial agents [34]. A MIC is generally regarded as the most basic laboratory measurement of the activity of an antimicrobial agent against an organism [35]. MIC was determined by the broth micro dilution method using 96-well micro-plates [36,37]. Pseudomonas aeruginosa showed an the same as the MIC value of 12.5 mg/mL of the tested compound 13b suggesting high inhibitory activity compared to that of Gentamicin. Also, compound 10a showed an MIC value of 3.9 against Escherichia coli which was the same MIC value of Gentamicin against Escherichia coli (Table 2).

The half maximal inhibitory concentration (IC50) is a measure of the effectiveness of a substance in inhibiting a specific biological or biochemical function. This quantitative measure indicates how much of a particular substance is needed to inhibit a given biological process by half. And here the biological function is the growth of microorganisms Aspergillus fumigatus, Syncephalastrum racemosum, Geotrichum candidum, Candida albicans, Streptococcus pneumoniae, Bacillus subtilis, Pseudomonas aeruginosa, and Escherichia coli (Table 3).

4. Experimental Section
4.1. General Information
All melting points were determined on an Electrothermal apparatus (Bibby Sci. Lim. Stone, Staffordshire, UK) and are uncorrected. IR spectra were recorded (KBr discs) on a FT-IR 8201 PC spectrophotometer (Shimadzu, Tokyo, Japan). 1H-NMR spectra were recorded in CDCl3 and DMSO-d6 solutions on a Gemini 300 MHz spectrometer (Varian, Mercury VX-300 NMR spectrometer, Bruker BioSpin GmbH, Rheinstetten, Germany) and chemical shifts are expressed in δ ppm units using TMS as an internal reference. Mass spectra were recorded on a Shimadzu GC-MS QP1000 EX instrument. (Tokyo, Japan) Elemental analyses were carried out at the Microanalytical Center of Cairo university. Hydrazonoyl halides 5a–d were prepared as previously reported [38,39,40,41]. Antimicrobial screening was performed at the Regional Center for Mycology and Biotechnology, Al-Azhar University, Cairo, Egypt.

4.1.1. General Procedure for the Synthesis of Thiadiazoles 9a–c and 10a–c
Mixtures of alkyl carbodithioate (3a, 3b, 4a or 4b) (5 mmol), hydrazonoyl halides (5a, 5b, or 5c) (5 mmol) and triethylamine (0.75 mL, 5 mmol) in ethanol (20 mL) were stirred at room temperature for 3 h. The resulting solid was collected and recrystallized from acetic acid (dioxane) to give 9a–c and 10a–c, respectively, in good yields.

Ethyl (Z)-5-(((Z)-(1,1’-diphenyl-3'-(p-tolyl)-1H,1'H-[3,4’-bipyrazol]-4-yl)methylene)hydrazono)-4-phenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate (9a). Yellow solid from glacial acetic acid, yield (1.9 g, 75%), mp: 176–177 °C; IR (KBr, cm−1): 3078 (=C–H), 2993–2862 (–C–H), 1708 (–C=O), 1608 (–C=N); 1H-NMR: δ 1.45 (t, 3H, –CH2CH3), 2.43 (s, 3H, 4-CH3C6H4), 4.44 (q, 2H, –OCH2CH3), 7.26–7.97 (m, 18H, Ar–H), 8.95 (s, 1H pyrazole-H-5); MS (m/z): 510 (M + 2, 9), 509 (M + 1, 32), 508 (M+, 72), 259 (52), 246 (41), 91 (57), 77 (100); Anal. Calcd. for C28H24N6O2S (508.59): C, 66.12; H, 4.76; N, 16.52; S, 6.30; found: C, 66.10; H, 4.75; N, 16.53; S, 6.33.

1-((Z)-5-(((Z)-(1,1'-Diphenyl-3'-(p-tolyl)-1H,1'H-[3,4'-bipyrazol]-4-yl)methylene)hydrazono)-4-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)ethan-1-one (9b). Yellow solid from glacial acetic acid, yield (2 g, 84%), mp: 165–166 °C; IR (KBr, cm−1): 3040 (=C–H), 2869 (–C–H), 1674 (–C=O), 1604 (–C=N); 1H-NMR: δ 2.43 (s, 3H, 4-CH3C6H4), 2.68 (s, 3H, –CO–CH3), 7.27–8.02 (m, 14H, Ar–H), 8.50 (s, 1H, –C=H), 8.85 (s, 1H, pyrazole-H-5); MS (m/z): 479 (M + 1, 25), 478 (M+, 32), 310 (35), 307 (34), 150 (33), 138 (38), 126 (30), 122 (39), 91 (37), 77 (26); Anal. Calcd. for C27H22N6OS (478.57): C, 67.75; H, 4.61; N, 17.58; S, 6.70; found: C, 67.76; H, 4.63; N, 17.56; S, 6.71.

((Z)-5-(((Z)-(1,1'-Diphenyl-3'-(p-tolyl)-1H,1'H-[3,4’-bipyrazol]-4-yl)methylene)hydrazono)-4-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)(phenyl)methanone (9c). Orange solid from dioxane, yield (2.27 g, 84%), mp: 264–265 °C; IR (KBr, cm−1): 2863 (C–H), 1700 (–C=O), 1608 (–C=N); 1H-NMR: δ 2.44 (s, 3H, 4-CH3C6H4), 7.27–8.49 (m, 19H, Ar–H), 8.54 (s, 1H, –C=H), 8.96 (s, 1H, pyrazole-H-5); MS (m/z): 542 (M + 2, 57), 541 (M + 1, 59), 540 (M+, 68), 525 (55), 510 (53), 494 (46), 479 (54), 468 (70), 458 (51), 439 (54), 421 (60), 412 (62), 371 (100), 355 (53), 282 (78), 135 (64), 105 (75); Anal. Calcd. for C32H24N6OS (540.64): C, 71.09; H, 4.47; N, 15.54; S, 5.93; found: C, 71.07; H, 4.48; N, 15.54; S, 5.95.

Ethyl (Z)-5-(((Z)-(3'-(furan-2-yl)-1,1'-diphenyl-1H,1'H-[3,4'-bipyrazol]-4-yl)methylene)hydrazono)-4-phenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate (10a). Yellow solid from ethanol, yield (2.2 g, 91%), mp: 171–173 °C; IR (KBr, cm−1): 3108 (=C-H), 2980 (–C–H), 1738 (–C=O), 1603 (–C=N), 1545 (C=C); 1H-NMR: δ 1.44 (t, 3H, –CH2CH3), 4.45 (q, 2H, –OCH2CH3), 6.55 (d, 1H, furyl-H), 6.94 (q, 1H, furyl-H), 7.27–8.03 (m, 11H, Ar–H + 1furyl-H), 8.47 (s, 1H, CH=N), 8.89 (s, 1H, pyrazole-H-5); MS (m/z): 485 (M + 1, 9), 484 (M+, 22), 221 (100), 135 (30), 120 (27), 92 (46), 78 (60); Anal. Calcd. for C25H20N6O3S (484.53): C, 61.97; H, 4.16; N, 17.34; S, 6.62; found: C, 61.99; H, 4.15; N, 17.35; S, 6.60.

1-((Z)-5-(((Z)-(3'-(Furan-2-yl)-1,1'-diphenyl-1H,1'H-[3,4'-bipyrazol]-4-yl)methylene)hydrazono)-4-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)ethan-1-one (10b). Yellow solid from glacial acetic acid, yield (1.3 g, 65%), mp: 200–202 °C; IR (KBr, cm−1): 3021 (=C–H), 2918 (–C–H), 1683 (C=O), 1604 (C=N), 1548 (C=C); 1H-NMR: δ 2.63 (s, 3H, CO–CH3), 6.55 (q, 1H, furyl), 6.89 (d, 1H, furyl), 7.27–7.96 (m, 11H, Ar–H + 1furyl-H), 8.28 (s, 1H, N=CH), 8.91 (s, 1H, pyrazole-H-5); MS (m/z): 454 (M+, 33), 426 (100), 221 (34), 193 (16), 119 (14), 92 (12), 78 (23), 65 (15); Anal. Calcd. for C24H18N6O2S (404.50): C, 63.40; H, 3.98; N, 18.50; S, 7.05; found: C, 63.42; H, 3.99; N, 18.49; S, 7.07.

5-(-((3-(Furan-2-yl)-1-phenyl-1H-pyrazol-4-yl)methylene)hydrazono)-4-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)(phenyl)methanone (10c). Red solid from glacial acetic acid, yield (2.1 g, 83%), mp: 228–230 °C; IR (KBr, cm−1): 3061 (=C–H), 1725 (–C=O), 1601 (–C=N), 1547 (C=C); 1H-NMR: δ 6.56 (q, 1H, furyl-H), 6.85 (d, 1H, furyl-H), 7.27–8.35 (m, 16H, Ar–H + 1furyl-H), 8.35 (s, 1H, CH=N), 8.90 (s, 1H, pyrazole-H-5); MS (m/z): 518 (M + 2, 1), 517 (M + 1, 5), 516 (M+, 31), 502 (12), 487 (97), 167 (10), 135 (25), 131 (10), 235 (17), 221 (49), 193 (24), 129 (17), 119 (11), 106 (100), 78 (45), 65 (30), 51 (45); Anal. Calcd. for C29H20N6O2S (516.57): C, 67.43; H, 3.90; N, 16.27; S, 6.21; found: C, 67.40; H, 3.89; N, 16.27; S, 6.23.

4.1.2. General Procedure for the Synthesis of Chalcones 12a–f
10% NaOH solution (0.2 g, 10 mL, 5 mmol) was added dropwise to a mixture of the appropriate 2-acetylfuran (0.54 g, 5 mmol) or 4-methylacetophenone (0.67 mL, 5 mmol) and the appropriate of 1-phenyl-3-(p-tolyl)-1H-pyrazole-4-carbaldehyde (1a) (1.3 g, 5 mmol), 3-(furan-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde (1.2 g, 5 mmol) (1b) or furfuraldehyde (1c) (0.48 g, 5 mmol) in ethanol (30 mL), at 0–5 °C while stirring. The precipitate that formed was filtered, washed with ethanol (10 mL), and recrystallized from ethanol to give 12a–f, respectively.

(E)-3-(Furan-2-yl)-1-(p-tolyl)prop-2-en-1-one (12a). Mp: 64–65 °C (lit. mp: 62–64 °C) [42].

(E)-1-(Furan-2-yl)-3-(3-(furan-2-yl)-1-phenyl-1H-pyrazol-4-yl)prop-2-en-1-one (12b). Yellow solid from ethanol, yield (1.5 g, 90%), mp: 155–156 °C; IR (KBr, cm−1): 3103 (=C–H), 1652 (C=O); 1H-NMR: δ 6.54 (q, 1H, furyl-H), 6.59 (q, 1H, furyl-H), 6.90 (q, 1H, furyl-H), 7.27–8.33 (m, 11H, ArH’s + 2CH=CH + 3furyl-H + pyrazole-H-5); MS (m/z): 332 (M + 2, 2), 331 (M + 1, 16), 330 (M+, 100), 314 (1), 300 (22), 242 (4), 270 (25), 214 (5), 91 (7); Anal. Calcd. for C20H14N2O3 (330.34): C, 72.72; H, 4.27; N, 8.48; found: C, 72.69; H, 4.28; N, 8.49.

(E)-3-(3-(Furan-2-yl)-1-phenyl-1H-pyrazol-4-yl)-1-(p-tolyl)prop-2-en-1-one (12c). Yellow solid, yield (1.63 g, 92%), mp: 146–147 °C; IR (KBr, cm−1): 3122 (=C-H aromatic), 3069 (=C–H), 2919 (–C–H), 1651 (C=O); 1H-NMR: δ 2.44 (s, 3H, 4-CH3C6H4), 6.54 (q, 1H, furyl-H), 6.89 (d, 1H, furyl-H), 7.26–8.19 (m, 12H, Ar–H’s + 2H + 1furyl-H), 8.25 (s, 1H, pyrazole-H-5); MS (m/z): 355 (M + 1, 2), 354 (M+, 7), 308 (20), 281 (25), 234 (43), 209 (27), 208 (42), 207 (28), 181 (13), 180 (43), 179 (20), 178 (15), 168 (16), 167 (36), 166 (100), 154 (13), 153 (44), 152 (32), 140 (38), 139 (10), 127 (13), 126 (10), 115 (16), 114 (10), 113 (13), 63 (10), 29 (30), 27 (13); Anal. Calcd. for C23H18N2O2 (354.40): C, 77.95; H, 5.12; N, 7.90; found: C, 77.97; H, 5.10; N, 7.91.

(E)-3-(1-Phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)-1-(p-tolyl)prop-2-en-1-one (12d). mp: 135–136 °C (lit. mp.: 101–103 °C) [43].

(E)-1,3-di(Furan-2-yl)prop-2-en-1-one (12e). Mp: 89–90 °C (lit. mp: 88–90 °C) [39].

1-(Furan-2-yl)-3-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)prop-2-en-1-one (12f) Yellow solid, yield (1.5 g, 86%), mp: 154–155 °C; IR (KBr, cm−1): 3138 (=C–H aromatic), 3105 (=C–H), 2922 (C–H), 1649 (C=O); 1H-NMR: δ 2.44 (s, 3H, 4-CH3C6H4), 6.56 (q, 1H, furyl-H), 7.23–7.97 (m, 13H, ArH’s + 2CH=CH + 2furyl-H), 8.35 (s, 1H, pyrazole-H-5); MS (m/z): 356 (M + 2, 3), 355 (M + 1, 20), 354 (100), 339 (11), 273 (17), 188 (10), 186 (20), 172 (20), 171 (24), 170 (17), 157 (10), 156 (17), 143 (11), 142 (11), 130 (24), 129 (14), 128 (15); Anal. Calcd. for C23H18N2O2 (354.40): C, 77.95; H, 5.12; N, 7.90; found: C, 77.97; H, 5.14; N, 7.88.

4.1.3. Synthesis of Carbothioamide Derivatives 13a–f
Mixtures of chalcones 12a–f (5 mmol) and thiosemicarbazide (0.46 g, 5 mmol) in ethanol (20 mL) were refluxed for 3 h. The resulting solid was collected and recrystallized from acetic acid to give 13a–f, respectively.

5-(Furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (13a). Mp: 190–191 °C. (lit. mp: 280–282 °C) [44].

3’,5-di(Furan-2-yl)-1'-phenyl-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carbothioamide (13b). Yellow solid, yield (1.7 g, 85%), mp: 285–287 °C; IR (KBr, cm−1): 3334 (N–H), 3120 (=C–H); 1H-NMR: δ 3.15 (dd, 1H, pyrazoline-H), 3.90 (q, 1H, pyrazoline-H), 6.20 (dd, 1H, pyrazoline-H), 6.65 (m, 2H, furyl-H), 6.67 (q, 1H, furyl-H), 7.05 (d, 1H, furyl-H), 7.44–7.91 (m, 9H, Ar–H + 1furyl-H + 2N–H), 8.95 (s, 1H, pyrazole-H-5); MS (m/z): 404 (M + 1, 2), 403 (M+, 9), 300 (6), 256 (1), 228 (10), 209 (36), 196 (100), 181 (58), 164 (50), 136 (25), 121 (6), 93 (9), 77 (7); Anal. Calcd. for C21H17N5O2S (403.46): C, 62.52; H, 4.25; N, 17.36; S, 7.95; found: C, 62.55; H, 4.26; N, 17.34; S, 7.94.

3’-(Furan-2-yl)-1'-phenyl-5-(p-tolyl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carbothioamide (13c). Yellow solid, yield (1.7 g, 80%), mp: 263–265 °C; IR (KBr, cm−1): 3265 (N–H), 3136 (=C–H aromatic), 3048 (=C–H), 2917 (–C–H); 1H-NMR: δ 2.34 (s, 3H, 4-CH3C6H4), 3.18 (dd, 1H, pyrazoline-H), 3.93 (q, 1H, pyrazoline-H), 6.16 (dd, 1H, pyrazoline-H), 6.65–7.84 (m, 14H, Ar–H + 3furyl-H + 2N–H), 8.08 (s, 1H, pyrazole-H-5); MS (m/z): 427 (M+, 5), 408 (11), 386 (18), 344 (25), 302 (48), 260 (100), 231 (6), 203 (3), 153 (1); Anal. Calcd. for C24H21N5OS (427.52): C, 67.43; H, 4.95; N, 16.38; S, 7.50; found: C, 67.39; H, 4.95; N, 16.38; S, 7.52.

1’-Phenyl-3’,5-di-p-tolyl-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carbothioamide (13d). White solid from dioxane, yield (1.7 g, 75%), mp: 276–277 °C; IR (KBr, cm−1): 3430; 3115 (N–H), 3046 (=C–H aromatic), 2918 (–C–H); 1H-NMR: δ 2.34 (s, 3H, 4-CH3C6H4), 2.35 (s, 3H, 4-CH3C6H4), 3.18 (dd, 1H, pyrazoline-H), 3.93 (q, 1H, pyrazoline-H), 6.16 (dd, 1H, pyrazoline-H), 6.66–7.82 (m, 15H, Ar–H + 2N–H), 8.07 (s, 1H, pyrazole-H-5); MS (m/z): 452 (M + 1, 6), 253 (17), 250 (13), 225 (16), 221 (10), 206 (19), 193 (20), 174 (14), 151 (9), 142 (29), 116 (10), 110 (16), 108 (17), 107 (16), 91 (100), 84 (43), 82 (26), 79 (20), 82 (26), 77 (12); Anal. Calcd. for C27H25N5S (451.59): C, 71.81; H, 5.58; N, 15.51; S, 7.10; found: C, 71.79; H, 5.57; N, 15.52; S, 7.12.

3,5-di(Furan-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (13e). Mp: 164–166 °C. (lit. mp: 162–163 °C) [45].

5-(Furan-2-yl)-1'-phenyl-3'-(p-tolyl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carbothioamide (13f). White solid, yield (1.6 g, 76%), mp: 247–248 °C;IR (KBr, cm−1): 3255 (N–H), 3145 (=C–H), 2919 (–C–H); 1H-NMR: δ 2.37 (s, 3H, 4-CH3C6H4), 3.05 (dd, 1H, pyrazoline-H), 3.85 (q, 1H, pyrazoline-H), 6.06 (dd, 1H, pyrazoline-H), 6.65–7.90 (m, 14H, Ar–H + 3furyl-H + 2N–H), 8.01 (s, 1H, pyrazole-H-5); MS (m/z): 427 (M+, 7), 384 (8), 354 (10), 325 (9), 296 (6), 270 (5), 254 (11), 240 (8), 213 (9), 103 (100), 75 (32); Anal. Calcd. for C24H21N5OS (427.52): C, 67.43; H, 4.95; N, 16.38; S, 7.50; found: C, 67.41; H, 4.95; N, 16.37; S, 7.51.

4.1.4. 5-Arylazothiazole Derivatives 14a–f and 15a–f
Method A 
Mixtures of the appropriate thioamides 13a–f (5 mmol), the appropriate 5b and 5c (5 mmol) and triethylamine (0.75 mL, 5 mmol) in ethanol (20 mL) were refluxed for 3 h. The resulting solid was collected and recrystallized from acetic acid (or dioxane) to give 14a–f and 15a–f, respectively.

Method B
Benzenediazonium chloride (5 mmol), which was prepared from aniline (0.45 mL, 5 mmol), hydrochloric acid (6 N, 6 mL), and sodium nitrite (0.35 g, 5 mmol), was added dropwise with stirring to a cold solution of 2-(5-(furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole (16) (1.92 g, 5 mmol) and sodium acetate trihydrate (1.3 g, 10 mmol) in ethanol (50 mL). The reaction mixture was stirred in an ice bath at 0–5 °C for 3 h. The result solid was collected and recrystallized to give a product identical in all aspects (mp, mixed mp. and spectra) with 15a.

(E)-2-(3-(Furan-2-yl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-methyl-5-(phenyldiazenyl)-thiazole (14a). Red solid, yield (1.5 g, 70%), mp: 179–180 °C; IR (KBr, cm−1): 2920 (–C–H); 1H-NMR: δ 2.37 (s, 3H, 4-CH3C6H4), 2.50 (s, 3H, –CH3), 3.56 (dd, 1H, pyrazoline-H), 3.90 (dd, 1H, pyrazoline-H), 5.90 (dd, 1H, pyrazoline-H), 6.43 (dd, 1H, furyl-H), 6.52 (dd, 1H, furyl-H), 7.31–7.76 (m, 10H, Ar–H + 1furyl-H); MS (m/z): 427 (M+, 1), 326 (12), 236 (16), 232 (14), 206 (39), 204 (11), 194 (31), 147 (51), 146 (14), 134 (23), 133 (41), 129 (11), 121 (32), 118 (12), 117 (100), 115 (10), 107 (24), 91 (17), 73 (24); Anal. Calcd. for C24H21N5OS (427.52): C, 67.43; H, 4.95; N, 16.38; S, 7.50; found: C, 67.41; H, 4.94; N, 16.37; S, 7.51.

(E)-2-(3',5-Di(furan-2-yl)-1'-phenyl-3,4-dihydro-1'H,2H-[3,4'-bipyrazol]-2-yl)-4-methyl-5-(phenyldiazen-yl)-thiazole (14b). Red solid, yield (1.5 g, 55%), mp: 275–277 °C; IR (KBr, cm−1): 3146 (=C–H), 2922 (–C–H); 1H-NMR: δ 2.49 (s, 3H, –CH3), 3.13 (dd, 1H, pyrazoline-H), 3.97 (dd, 1H, pyrazoline-H), 6.17 (dd, 1H, pyrazoline-H), 6.65–7.91 (m, 16H, Ar–H + 3-furyl-H), 8.95 (s, 1H, pyrazole-H-5); MS (m/z): 545 (4), 520 (14), 505 (35), 504 (10), 492 (13), 491 (17), 478 (10), 460 (10), 270 (48), 252 (17), 241 (18), 223 (10), 176 (19), 121 (40), 106 (11), 83 (10), 71 (11); Anal. Calcd. for C30H23N7O2S (545.61): C, 66.04; H, 4.25; N, 17.97; S, 5.88; found: C, 66.02; H, 4.24; N, 17.98; S, 5.89.

(E)-2-(3’-(Furan-2-yl)-1’-phenyl-5-(p-tolyl)-3,4-dihydro-1'H,2H-[3,4’-bipyrazol]-2-yl)-4-methyl-5-(phenyl-diazenyl)-thiazole (14c). Red solid, yield (1.7 g, 60%), mp: 250–252 °C; IR (KBr, cm−1): 3139 (=C–H), 2917 (–C–H); 1H-NMR: δ 2.30 (s, 3H, 4-CH3C6H4), 2.50 (s, 3H, –CH3), 3.18 (dd, 1H, pyrazoline-H), 3.97 (dd, 1H, pyrazoline-H), 6.19 (dd, 1H, pyrazoline-H), 6.65–7.88 (m, 17H, Ar–H + 3furyl-H), 8.08 (s, 1H, pyrazole-H-5); MS (m/z): 569 (M+, 4), 484 (16), 454 (14), 358 (42), 317 (60), 289 (34), 230 (34), 130 (16), 103 (26), 77 (14); Anal. Calcd. for C33H27N7OS (569.68): C, 69.57; H, 4.78; N, 17.21; S, 5.63; found: C, 69.55; H, 4.78; N, 17.20; S, 5.64.

(E)-4-Methyl-2-(1'-phenyl-3',5-di-p-tolyl-3,4-dihydro-1'H,2H-[3,4'-bipyrazol]-2-yl)-5-(phenyldiazenyl)-thiazole (14d). Orange solid, yield (2.1 g, 70%), mp: 210–211 °C; IR (KBr, cm−1): 3136 (=C–H aromatic), 3051 (=C–H), 2950 (–C–H); 1H-NMR: δ 2.40 (s, 6H, 4-CH3C6H4), 2.63 (s, 3H, –CH3), 3.65; 3.9 (m, 2H, pyrazoline-H), 5.1 (q, 1H, pyrazoline-H), 6.99–8.95 (m, 19H, Ar–H + pyrazole-H-5); MS (m/z): 593 (M+, 2), 581 (12), 578 (16), 574 (35), 300 (33), 299 (100), 298 (11), 288 (11), 287 (19), 286 (77), 285 (15), 241 (10), 227 (24), 211 (18); Anal. Calcd. for C36H31N7S (593.74): C, 72.82; H, 5.26; N, 16.51; S, 5.40; found: C, 72.85; H, 5.27; N, 16.49; S, 5.39.

(E)-2-(3,5-Di(furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-4-methyl-5-(phenyldiazenyl)-thiazole (14e). Red solid, yield (1.3 g, 66%), mp: 201–203 °C; IR (KBr, cm−1): 3122 (=C–H), 2950 (–C–H); 1H-NMR: δ 2.54 (s, 3H, –CH3), 3.50 (dd, 1H, pyrazoline-H), 3.89 (dd, 1H, pyrazoline-H), 5.90 (dd, 1H, pyrazoline-H), 6.43–6.73 (m, 3H, furyl-H), 7.14 (t, 1H, furyl-H), 7.37–7.97 (m, 7H, Ar–H +2 furyl-H); MS (m/z): 405 (M+2, 3), 404 (M + 1, 21), 403 (M+, 75), 388 (41), 361 (64), 275 (12), 146 (7), 130 (14); Anal. Calcd. for C21H17N5O2S (403.46): C, 62.52; H, 4.25; N, 17.36; S, 7.95; found: C, 62.49; H, 4.25; N, 17.37; S, 7.96.

(E)-2-(5-(Furan-2-yl)-1'-phenyl-3'-(p-tolyl)-3,4-dihydro-1'H,2H-[3,4’-bipyrazol]-2-yl)-4-methyl-5-(phenyldiazenyl)-thiazole (14f). Orange solid, yield (2.1 g, 75%), mp: 216–219 °C; IR (KBr, cm−1): 3120 (=C–H), 2914 (–C–H); 1H-NMR: δ 2.39 (s, 3H, 4-CH3C6H4), 2.47 (s, 3H, –CH3), 4.49 (q, 2H, pyrazoline-H), 5.95 (q, 1H, pyrazoline-H), 6.70 (dd, 1H, furyl-H), 7.05 (d, 1H, furyl-H),7.28–7.61 (m, 15H, Ar–H + 1furyl-H), 8.52 (s, 1H, pyrazole-H-5); MS (m/z): 569 (M+, 7), 553 (10), 398 (12), 370 (15), 248 (51), 235 (100), 91 (27); Anal. Calcd. for C33H27N7OS (569.68): C, 69.57; H, 4.78; N, 17.21; S, 5.63; found: C, 69.58; H, 4.79; N, 17.22; S, 5.62.

(E)-2-(5-(Furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenyl-5-(phenyldiazenyl)-thiazole (15a). Orange solid, yield (1.9 g, 76%), mp: 233–234 °C; IR (KBr, cm−1): 3147 (=C–H), 2930 (–C–H); 1H-NMR: δ 2.38 (s, 3H, 4-CH3C6H4), 3.60 (dd, 1H, pyrazoline-H), 4.00 (dd, 1H, pyrazoline-H), 6.00 (dd, 1H, pyrazoline-H), 6.46 (q, 1H, furyl-H), 6.65 (d, 1H, furyl-H), 7.33–8.05 (m, 15H, Ar–H + 1furyl-H); MS (m/z): 489 (M+, 2), 428 (10), 335 (18), 321 (10), 293 (18), 163 (11), 165 (9), 155 (100), 92 (10), 91 (68), 43 (9); Anal. Calcd. for C29H23N5OS (489.59): C, 71.14; H, 4.74; N, 14.30; S, 6.55; found: C, 71.15; H, 4.73; N, 14.31; S, 6.52.

(E)-2-(3',5-di(Furan-2-yl)-1'-phenyl-3,4-dihydro-1'H,2H-[3,4'-bipyrazol]-2-yl)-4-phenyl-5-(phenyldiazenyl)-thiazole (15b). Orange solid, yield (1.8 g, 60%), mp: 270–272 °C; IR (KBr, cm−1): 3150 (=C–H); 1H-NMR: δ 3.08 (q, 1H, pyrazoline-H), 3.96 (q, 1H, furyl-H), 6.18 (q, 1H, pyrazoline-H), 6.66–8.10 (m, 22H, Ar–H + pyrazole-H-5 + 6furyl-H); MS (m/z): 607 (M+, 2), 331 (14), 284 (100), 169 (94), 127 (17), 109 (57), 43 (86); Anal. Calcd. for C35H25N7O2S (607.68): C, 69.18; H, 4.15; N, 16.13; S, 5.28; found: C, 69.19; H, 4.16; N, 16.15; S, 5.23.

(E)-2-(3'-(Furan-2-yl)-1'-phenyl-5-(p-tolyl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazol]-2-yl)-4-phenyl-5-(phenyldiazenyl)-thiazole (15c). Orange solid, yield (2.3 g, 74%), mp: 240–242 °C; IR (KBr, cm−1): 3139 (=C–H), 2920 (–C–H); 1H-NMR: δ 2.34 (s, 3H, 4-CH3C6H4), 3.18 (dd, 1H, pyrazoline-H), 3.39 (dd, 1H, pyrazoline-H), 6.11 (dd, 1H, pyrazoline-H), 6.64–8.08 (m, 23H, Ar–H + pyrazole-H-5 + 3furyl-H); MS (m/z): 631 (M+, 4), 477 (9), 409 (65), 297 (6), 271 (5), 245 (8), 227 (11), 203 (13), 149 (17), 135 (49), 107 (31), 69 (100); Anal. Calcd. for C38H29N7OS (631.75): C, 72.25; H, 4.63; N, 15.52; S, 5.08; found: C, 72.25; H, 4.62; N, 15.50; S, 5.10.

(E)-4-Phenyl-2-(1'-phenyl-3',5-di-p-tolyl-3,4-dihydro-1'H,2H-[3,4'-bipyrazol]-2-yl)-5-(phenyldiazenyl)-thiazole (15d). Red solid, yield (1.5 g, 45%), mp: 208–209 °C; IR (KBr, cm−1): 3142 (=C–H), 2924 (–C–H); 1H-NMR: δ 2.50 (s, 6H, 4-CH3C6H4), 3.36 (q, 1H, pyrazoline-H), 3.63 (q, 1H, pyrazoline-H), 5.30 (q, 1H, pyrazoline-H), 7.36–9.00 (m, 24H, Ar–H + pyrazole-H-5); MS (m/z): 655 (M+, 1), 498 (10), 339 (10), 281 (17), 243 (51), 242 (62), 210 (12), 171 (32), 156 (25), 73 (35), 71 (76), 41 (26), 39 (14), 27 (19); Anal. Calcd. for C41H33N7S (655.81): C, 75.09; H, 5.07; N, 14.95; S, 4.89; found: C, 75.10; H, 5.05; N, 14.96; S, 4.88.

(E)-2-(3,5-di(Furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenyl-5-(phenyldiazenyl)-thiazole (15e). Red solid, yield (1.3 g, 57%), mp: 181–183 °C; IR (KBr, cm−1): 3100 (=C–H); 1H-NMR: δ 4.00 (m, 2H, pyrazoline-H), 6.00 (q, 1H, pyrazoline-H), 6.46; 6.64; 6.74 (m, 3H, furyl-H), 7.16 (d, 1H, furyl-H), 7.41–8.27 (m, 12H, Ar–H + 2furyl-H); MS (m/z): 465 (M+, 3), 271 (29), 253 (70), 233 (16), 221 (100), 105 (10); Anal. Calcd. for C26H19N5O2S (465.53): C, 67.08; H, 4.11; N, 15.04; S, 6.89; found: C, 67.10; H, 4.09; N, 15.05; S, 6.86.

(E)-2-(5-(Furan-2-yl)-1'-phenyl-3'-(p-tolyl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazol]-2-yl)-4-phenyl-5-(phenyldiazenyl)-thiazole (15f). Orange, yield (1.7 g, 53%), mp: 249–250 °C; IR (KBr, cm−1): 3150 (=C–H), 2922 (–C–H); 1H-NMR: δ 2.37 (s, 3H, 4-CH3C6H4), 3.30 (dd, 1H, pyrazoline-H), 3. 90 (dd, 1H, pyrazoline-H), 6.16 (q, 1H, pyrazoline-H), 6.65 (q, 1H, furyl-H), 7.01 (q, 1H, furyl-H), 7.82–8.10 (m, 21H, Ar–H + pyrazole-H-5 + 1furyl-H); MS (m/z): 633 (M + 2, 1), 632 (M + 1, 8), 631 (M+, 28), 630 (60), 380 (7), 337 (14), 322 (37), 321 (100), 310 (47), 292 (13), 109 (13), 97 (24), 83 (29), 69 (35); Anal. Calcd. for C38H29N7OS (631.75): C, 72.25; H, 4.63; N, 15.52; S, 5.08; found: C, 72.23; H, 4.63; N, 15.51; S, 5.09.

2-(5-(Furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole (16). A mixture of 5-(furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (1.42 g, 5 mmol) and ω-bromo-acetophenone (0.99 g, 5 mmol) in ethanol (30 mL) was heated under reflux for 2 h to give 2-(5-(Furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole (15) as a white precipitate which was washed with water and recrystallized from glacial acetic acid a white solid, yield (1.9 g, 71%), mp: 221 °C; IR (KBr, cm−1): 3100; 3041 (=C–H), 2943 (–C–H), 1717 (–C=O amide); 1H-NMR: δ 2.45 (s, 3H, 4-CH3C6H4), 3.77 (dd, 1H, pyrazoline-H), 3.93 (dd, 1H, pyrazoline-H), 6.34 (q, 1H, pyrazoline-H), 6.70–7.91 (m, 13H, Ar–H + 3furyl-H + 1thiazole H-5); MS (m/z): 385 (M+, 7%), 381 (3%), 378 (10%), 374 (23%), 369 (51%), 263 (13%), 262 (100%), 260 (12%), 223 (12%), 216 (20%), 215 (12%), 77 (33%), 76 (16%); Anal. Calcd. for C23H19N5O2S (385.48): C, 71.66; H, 4.97; N, 10.90; S, 8.32; found: C, 71.63; H, 4.98; N, 10.92; S, 8.32.

4.1.5. (2-Phenylhydrazono)thiazol-4(5H)-one Derivatives 18a–e
Method A
Equimolar amounts of the appropriate thioamides 13a–d, 13f and ethyl 2-chloro-2-(2-phenylhydrazono)acetate with triethylamine (5 mmol) in ethanol (25 mL) were refluxed for 2 h. The solid so formed was collected and crystallized from glacial acetic acid to afford 2-phenylhydrazono)thiazol-4(5H)-one 18a–e, respectively.

Method B
Benzenediazonium chloride (5 mmol), which prepared from aniline (0.45 mL, 5 mmol), hydrochloric acid (6 N, 6 mL), and sodium nitrite (0.35 g, 5 mmol), was added dropwise with stirring to a cold solution of 19 (5 mmol) and sodium acetate trihydrate (1.3 g, 10 mmol) in ethanol (50 mL). The reaction mixture was stirred in ice bath for 3 h. The resulting solid was collected and crystallized to give a product identical in all aspects (mp, mixed mp, and spectra) with 18a.

(E)-2-(5-(Furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-5-(2-phenylhydrazono)-thiazol-4(5H)-one (18a). Yellow solid, yield (1.4 g, 67%), mp: 247–248 °C; IR (KBr, cm−1): 3432 (N–H), 2970; 2921 (–C–H), 1717 (–C=O amide); 1H-NMR: δ 2.39 (s, 3H, 4-CH3C6H4), 3.63 (dd, 1H, pyrazoline-H), 4.04 (dd, 1H, pyrazoline-H), 5.96 (q, 1H, pyrazoline-H), 6.44 (q, 1H, furyl-H), 6.54 (d, 1H, furyl-H), 6.9–7.78 (m, 10H, Ar–H + 1furyl-H), 10.4 (s, 1H, N–H); MS (m/z): 431 (M + 2, 1), 430 (M + 1, 29), 429 (M+, 100), 413 (15), 346 (15), 345 (40), 316 (10), 264 (23), 263 (11), 248 (10), 228 (58), 227 (25), 226 (16), 214 (44), 212 (12), 200 (12), 198 (11), 196 (16), 186 (14), 172 (11), 170 (13), 158 (14), 157 (10), 156 (13), 146 (17), 144 (18), 130 (16), 115 (10); Anal. Calcd. for C23H19N5O2S (429.49): C, 64.32; H, 4.46; N, 16.31; S, 7.47; found: C, 64.33; H, 4.46; N, 16.32; S, 7.44.

(Z)-2-(3',5-di(Furan-2-yl)-1'-phenyl-3,4-dihydro-1'H,2H-[3,4'-bipyrazol]-2-yl)-5-(2-phenylhydrazono)-thiazol-4(5H)-one (18b). Yellow solid, yield (1.7 g, 63%), mp: 284–285 °C; IR (KBr, cm−1): 3407 (N–H), 3044 (=C–H), 2852 (–C–H), 1635 (C=O); 1H-NMR: δ 3.08 (dd, 1H, pyrazoline-H), 3.90 (dd, 1H, pyrazoline-H), 6.19 (dd, 1H, pyrazoline-H), 6.66–7.90 (m, 17H, Ar–H + 1N–H + 6furyl-H), 8.09 (s, 1H, pyrazole-H-5); MS (m/z): 549 (M + 2, 1), 548 (M + 1, 6), 547 (M+, 16), 374 (100), 329 (7), 254 (19), 227 (61), 212 (17), 173 (77), 91 (9), 77 (7); Anal. Calcd. for C29H21N7O3S (547.59): C, 63.61; H, 3.87; N, 17.91; S, 5.86; found: C, 63.61; H, 3.88; N, 17.93; S, 5.80.

(E)-2-(3'-(Furan-2-yl)-1'-phenyl-5-(p-tolyl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazol]-2-yl)-5-(2-phenylhydrazono)-thiazol-4(5H)-one (18c). Yellow solid, yield (1.5 g, 54%), mp: 245–247 °C; IR (KBr, cm−1): 3396 (N-H), 3140 (=C–H), 2990 (–C–H), 1715 (–C=O); 1H-NMR: δ 2.34 (s, 3H, 4-CH3C6H4), 3.18 (dd, 1H, pyrazoline-H), 3.90 (dd, 1H, pyrazoline-H), 6.17 (dd, 1H, pyrazoline-H), 6.65–8.08 (m, 19H, Ar–H + 3furyl-H + 1N–H + 1pyrazole-H-5); MS (m/z): 571 (M+, 2), 569 (4), 553 (10), 398 (12), 370 (15), 248 (51), 235 (100), 155 (12), 107 (10), 91 (27), 77 (2), 55 (9); Anal. Calcd. for C32H25N7O2S (571.65): C, 67.23; H, 4.41; N, 17.15; S, 5.61; found: C, 67.25; H, 4.41; N, 17.13; S, 5.60.

(E)-2-(1'-Phenyl-3',5-di-p-tolyl-3,4-dihydro-1'H,2H-[3,4'-bipyrazol]-2-yl)-5-(2-phenylhydrazono)-thiazol-4(5H)-one (18d). Yellow solid, yield (1.6 g, 55%), mp: 278–279 °C; IR (KBr, cm−1): 3431 (N–H), 3140 (=C–H), 2919 (–C–H), 1715 (–C=O); 1H-NMR: δ 2.34 (s, 3H, 4-CH3C6H4), 2.36 (s, 3H, CH3), 3.30 (dd, 1H, pyrazoline-H), 3.85 (dd, 1H, pyrazoline-H), 6.10 (dd, 1H, pyrazoline-H), 7.24–8.08 (m, 20H, 18Ar-H + 1N–H + pyrazole-H-5); MS (m/z): 595 (M+, 1), 578 (11), 554 (6), 397 (10), 340 (7), 279 (100), 263 (4), 236 (29), 193 (28), 91 (1); Anal. Calcd. for C35H29N7OS (595.72): C, 70.57; H, 4.91; N, 16.46; S, 5.38; found: C, 70.58; H, 4.92; N, 16.49; S, 5.32.

(E)-2-(5-(Furan-2-yl)-1'-phenyl-3'-(p-tolyl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazol]-2-yl)-5-(2-phenylhydrazono)-thiazol-4(5H)-one (18e). Yellow solid, yield (2.1 g, 75%), mp: 294–296 °C; IR (KBr, cm−1): 3433 (N-H), 3137 (=C–H), 2921 (–C–H), 1708 (–C=O); 1H-NMR: δ 2.37 (s, 3H, 4-CH3C6H4), 3.40 (dd, 1H, pyrazoline-H), 4.10 (dd, 1H, pyrazoline-H), 5.90 (q, 1H, pyrazoline-H), 6.72 (q, 1H, furyl-H), 6.90–7.99 (m, 16H, Ar–H + 2furyl-H), 8.52 (s, 1H, pyrazole-H-5), 10.33(s, 1H, N-H); MS (m/z): 571 (M+, 2), 553 (10), 398 (12), 370 (15), 248 (51), 235 (100), 155 (12), 107 (10), 91 (27), 71 (4); Anal. Calcd. for C32H25N7O2S (571.65): C, 67.23; H, 4.41; N, 17.15; S, 5.61; found: C, 67.20; H, 4.41; N, 17.13; S, 5.64.

2-(5-(Furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-thiazol-5(4H)-one (19) Equimolar amounts of 5-(furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (13a, 1.42 g, 5 mmol) and ethyl chloroacetate (0.61 g, 5 mmol) in ethanol (25 mL) were heated under reflux for 2 h, then allowed to cool at room temperature, the solid so formed was collected and recrystallized from dioxane to give 18 as a pale yellow solid, yield (1.2 g, 72%), mp: 244–245 °C; IR (KBr, cm−1): 3143 (=C–H aromatic), 3039 (=C–H), 2991 (–C–H), 1697 (C=O); 1H-NMR: δ 2.44 (s, 3H, 4-CH3C6H4), 3.61 (dd, 1H, pyrazoline-H), 3.92 (s, 2H, thiazole-H), 3.95 (dd, 1H, pyrazoline-H), 5.85 (q, 1H, pyrazoline-H), 6.42–7.76 (m, 7H, 4Ar-H + 3furyl-H); MS (m/z): 327 (M + 2, 1), 326 (M + 1, 10), 325 (M+, 50), 308 (47), 293 (100), 275 (51), 101 (35), 77 (40), 69 (67); Anal. Calcd. for C17H15N3O2S (325.38): C, 62.75; H, 4.65; N, 12.91; S, 9.85; found: C, 62.74; H, 4.67; N, 12.92; S, 9.81.

4.1.6. General Procedure for the Synthesis of Compounds 20 and 27
Equimolar amounts of the appropriate pyrazole aldehyde 1a or 2b (10 mmol), N,N`-dimethylbarbituric acid (1.56 g, 10 mmol), thiourea (0.76 g, 10 mmol) and conc. hydrochloric acid (5 mL) in ethanol (25 mL) were heated under refluxed for 1 h. The reaction mixture was allowed to cool to room temperature and the precipitate was filtered and crystallized from dioxane to give compounds 20 and 27, respectively.

1,3-Dimethyl-5-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)-7-thioxo-5,6,7,8-tetrahydro-pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (20). Yellow solid, yield (4.3 g, 94%), mp: 267–268 °C; IR (KBr, cm−1): 3434 (N–H), 3175 (=C-H aromatic), 3019 (C=H), 2921 (–C–H), 1669 (C=O); 1H-NMR: δ 2.45 (s, 3H, 4-CH3C6H4), 3.40 (s, 3H, N–CH3), 3.44 (s, 3H, N–CH3), 7.27–7.93 (m, 11H, Ar-H + pyrimidine-H-5 + pyrazole-H-5), 8.62 (s, 1H, N–H), 9.88 (s, 1H, N–H); MS (m/z): 460 (M + 2, 2), 459 (M + 1, 12), 458 (M+, 36), 426 (73), 398 (33), 394 (28), 383 (52), 368 (38), 367 (100), 365 (16), 305 (10), 289 (34); Anal. Calcd. for C24H22N6O2S (458.54): C, 62.86; H, 4.84; N, 18.33; S, 6.99; found: C, 62.86; H, 4.85; N, 18.34; S, 6.98.

5-(3-(Furan-2-yl)-1-phenyl-1H-pyrazol-4-yl)-1,3-dimethyl-7-thioxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (27). Brown solid, yield (3.6 g, 85%), mp: 186–187 °C; IR (KBr, cm−1): 3439 (N-H), 3170 (=C–H), 2954 (–C–H), 1664 (C=O); 1H-NMR: δ 3.44 (s, 6H, 2N–CH3), 6.59–7.90 (m, 10H, ArH + 3furyl-H + pyrimidine-H+ pyrazole-H-5), 9.13 (s, 1H, N–H), 9.85 (s, 1H, N–H); MS (m/z): 434 (M+1, 3), 433 (M+, 5), 310 (100), 296 (51), 238 (49), 168 (28), 166 (34), 150 (17), 139 (59), 138 (42), 125 (74), 99 (11), 83 (14), 43 (22); Anal. Calcd. for C21H18N6O3S (434.47): C, 58.05; H, 4.18; N, 19.34; S, 7.38; found: C, 58.01; H, 4.19; N, 19.36; S, 7.38.

4.1.7. General procedure for the Synthesis of Hexahydropyrimido[4,5-d][1,2,4]triazolo[4,3-a]pyrimidine Derivatives 26a–c and 28a,d
Equimolar amounts of 20 (2.29 g, 5 mmol) or 27 (2.17 g, 5 mmol) and the appropriate hydrazonyl halides 5a–d (5 mmol) in ethanol (25 mL) containing 5 drops of triethylamine was heated under reflux for 20 h. The reaction mixture was evaporated under reduced pressure and the resulting solid was washed several times with water and ether. The precipitates formed, were filtered and recrystallized to give:

Ethyl 7,9-dimethyl-6,8-dioxo-1-phenyl-5-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)-1,5,6,7,8,9-hexahydropyrimido[4,5-d][1,2,4]triazolo[4,3-a]pyrimidine-3-carboxylate (26a). White solid from glacial acetic acid, yield (2.4 g, 77%), mp: 250–251 °C; IR (KBr, cm−1): 3108 (=C–H aromatic), 3038 (=C–H), 2965; 2916 (–C–H), 1696 (C=O); 1H-NMR: δ 1.28 (t, 3H,–CH2CH3), 2.34 (s, 3H, 4-CH3C6H4), 2.82 (s, 3H, N–CH3), 2.86 (s, 3H, N–CH3), 4.30 (q, 2H,-OCH2CH3), 5.59 (s, 1H, pyrimidine-H), 6.88–7.7 (m, 14H, Ar–H), 7.77 (s, 1H, pyrazole-H-5); MS (m/z): 614 (M+, 9), 563 (6), 379 (10), 323 (54), 311 (30), 295 (100), 284 (11), 267 (19), 239 (4), 111 (12), 96 (22), 85 (18), 71 (26); Anal. Calcd. for C34H30N8O4 (614.65): C, 66.44; H, 4.92; N, 18.23; found: C, 66.43; H, 4.91; N, 18.21.

3-Benzoyl-7,9-dimethyl-1-phenyl-5-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)-7,9-dihydropyrimido[4,5-d][1,2,4]triazolo[4,3-a]pyrimidine-6,8(1H,5H)-dione (26b). White solid from toluene, yield (1.6 g, 50%), mp: 211–213 °C; IR (KBr, cm−1): 3049 (=C–H), 2920 (–C–H), 1695 (–C=O); 1H-NMR: δ 2.43 (s, 3H, 4-CH3C6H4), 2.80 (s, 3H, N–CH3), 2.88 (s, 3H, N–CH3), 5.85 (s, 1H, pyrimidine-H), 6.86–7.68 (m, 19H, Ar-H), 8.32 (s, 1H, pyrazole-H-5); MS (m/z): 646 (M+, 3), 645 (6), 662 (5), 406 (13), 389 (54), 256 (12), 239 (14), 195 (11), 168 (13), 151 (100), 135 (29), 106 (17), 85 (30); Anal. Calcd. for C38H30N8O3 (646.70): C, 70.58; H, 4.68; N, 17.33; found: C, 70.56; H, 4.68; N, 17.34.

7,9-Dimethyl-6,8-dioxo-N,1-diphenyl-5-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)-1,5,6,7,8,9-hexahydropyrimido[4,5-d][1,2,4]triazolo[4,3-a]pyrimidine-3-carboxamide (26c). White solid from glacial acetic acid, yield (2 g, 60%), mp: 258–259 °C; IR (KBr, cm−1): 3364 (N–H), 3136 (=C–H aromatic), 3054 (=C–H), 2921 (–C–H), 1690 (C=O); 1H-NMR: δ 2.42 (s, 3H, 4-CH3C6H4), 2.80 (s, 3H, N–CH3), 2.87 (s, 3H, N–CH3), 5.76 (s, 1H, pyrimidine-H), 6.86–7.68 (m, 19H, Ar-H), 7.78 (s, 1H, pyrazole-H-5), 8.55 (s, 1H, N–H); MS (m/z): 661 (M + 1, 3), 660 (M+, 7), 603 (9), 441 (11), 401 (1), 315 (29), 204 (100), 189 (46), 161 (12), 147 (56), 121 (3); Anal. Calcd. for C38H31N9O3 (661.71): C, 68.97; H, 4.72; N, 19.05; found: C, 68.93; H, 4.73; N, 19.07.

Ethyl 5-(3-(furan-2-yl)-1-phenyl-1H-pyrazol-4-yl)-7,9-dimethyl-6,8-dioxo-1-phenyl-1,5,6,7,8,9-hexahydropyrimido[4,5-d][1,2,4]triazolo[4,3-a]pyrimidine-3-carboxylate (28a). White solid from benzene, yield (2.2 g, 75%), mp: 249–251 °C; IR (KBr, cm−1): 3038 (=C–H), 2969 (–C–H), 1696 (C=O); 1H-NMR: δ 1.28 (t, 3H, –CH2CH3), 2.82 (s, 3H, N–CH3), 2.85 (s, 3H, N–CH3), 4.27 (q, 2H, –OCH2 CH3), 5.58 (s, 1H, pyrimidine-H), 6.87–7.69 (m, 13H, Ar–H + 3furyl-H), 7.75 (s, 1H, pyrazole-H-5); MS (m/z): 590 (M+, 1), 511 (2), 397 (10), 340 (7), 279 (100), 236 (29), 193 (28); Anal. Calcd. for C31H26N8O5 (590.59): C, 63.04; H, 4.44; N, 18.97; found: C, 63.01; H, 4.46; N, 18.91.

5-(3-(Furan-2-yl)-1-phenyl-1H-pyrazol-4-yl)-7,9-dimethyl-6,8-dioxo-N,1-diphenyl-1,5,6,7,8,9-hexahydropyrimido[4,5-d][1,2,4]triazolo[4,3-a]pyrimidine-3-carboxamide (28b). White solid from toluene, yield (1.7 g, 55%), mp: 145–146 °C; IR (KBr, cm−1): 3398 (N–H), 3130 (=C-H aromatic), 3028 (=C–H), 2949 (–C–H); 1H-NMR: δ 2.84 (s, 3H, N–CH3), 3.35 (s, 3H, N–CH3), 6.03 (s, 1H, pyrimidine-H), 6.53 (q, 1H, furyl-H), 6.91–7.67 (m, 17H, Ar–H + 2furyl-H), 8.73 (s, 1H, pyrazole-H-5), 8.54 (s, 1H, N–H); MS (m/z): 637 (M+, 7), 633 (17), 620 (24), 528 (11), 436 (25), 418 (34), 380 (24), 278 (18), 263 (66), 232 (34), 219 (100), 203 (57), 159 (89); Anal. Calcd. for C35H27N9O4 (637.65): C, 65.93; H, 4.27; N, 19.77; found: C, 65.90; H, 4.28; N, 19.73.

4.2. Antimicrobial Activity Assay
Chemical compounds under investigation were individually tested against a panel of Gram-positive and Gram-negative bacteria pathogens, and fungi. Antimicrobial tests were carried out using the agar well-diffusion method [46]. After the media had cooled and solidified, wells (6 mm in diameter) were made in the solidified agar, after that microbial inoculum was uniformly spread using sterile cotton swab on a sterile Petri dish containing nutrient agar (NA) medium or Sabouraud dextrose agar (SDA) media for bacteria and fungi, respectively. A 100 µL solution was prepared from 1 mL of DMSO by dissolving 1 mg of the compound. The inoculated plates were then incubated for 24 h at 37 °C for bacteria and yeast, 48 h at 28 °C for fungi. Negative controls were prepared using DMSO employed for dissolving the tested compound. Amphotericin B (1 mg/mL), ampicillin (1 mg/mL), and gentamicin (1 mg/mL) were used as standards for bacteria and fungi, respectively. After incubation, antimicrobial activity was evaluated by measuring the zone of inhibition against tested microorganisms. Antimicrobial activity was expressed as inhibition diameter zones in millimeters (mm). The experiment was carried out in triplicate and the average zones of inhibition ± S.D were calculated.

5. Conclusions
New series of novel functionalized 1,3,4-thiadiazoles, 1,3-thiazoles, and pyrimido[4,5-d][1,2,4]triazolo[4,3-a]pyrimidines containing pyrazole moieties were synthesized using hydrazonoyl halides as precursors and evaluated for their in vitro antibacterial, and antifungal activities. From the screening results, it can be seen Aspergillus fumigatus was susceptible to compounds 12b, 13b, 14b, 15b, and 15c when compared to the amphotericin B standard. Candida albicans was susceptible to compounds 12b and 13b when compared to the amphotericin B standard. Streptococcus pneumoniae was susceptible to compounds 12b, 13b, and 14b when compared to an ampicillin standard. Bacillus subtilis was susceptible to compounds 13b, 14b, and 15b when compared to ampicillin standard. Pseudomonas aeruginosa was susceptible to compounds 12b, 13b, 15a, and 26d when compared to Gentamicin standard. Escherichia coli was susceptible to compounds 10a, 12b, 13b, 14b, 15f, and 28a when compared to the gentamicin standard.

Acknowledgments
The authors would like to thank the Chemistry Department, Faculty of Science, Cairo University and National Center for Social and Criminological Research for their financial support to facilitate the publication of this study.

Sample Availability: Samples of the synthesized compounds are available from the authors.

Author Contributions
A.O.A. designed research and analyzed the data. M.N.M. performed experiments. All authors contributed wrote and approved the manuscript.

Conflicts of Interest
The authors declare no conflict of interest.

Schemes and Tables
molecules-21-01072-sch001_Scheme 1Scheme 1 Synthesis of 1,3,4-thiadiazole derivatives 9a–c and 10a–c.

molecules-21-01072-sch002_Scheme 2Scheme 2 Synthesis of thioamide derivatives 13a–f.

molecules-21-01072-sch003_Scheme 3Scheme 3 2-(5-(Furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-substituted-5-(phenyldiazenyl)thiazole 14a and 15a.

molecules-21-01072-sch004_Scheme 4Scheme 4 4,5-Dihydro-1H-pyrazol-1-yl)-4-phenyl-5-(phenyldiazenyl)thiazole derivatives 14b–f and 15b–f.

molecules-21-01072-sch005_Scheme 5Scheme 5 Synthesis of 2-(5-(furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-5-(2-phenyl-hydrazono)thiazol-4(5H)-one 18a.

molecules-21-01072-sch006_Scheme 6Scheme 6 Synthesis of 3,5-substituted 4,5-dihydro-1H-pyrazol-1-yl)-5-(2-phenylhydrazono)thiazol-4(5H)-one 18b–e.

molecules-21-01072-sch007_Scheme 7Scheme 7 Synthesis of 1,3-dimethyl-7-phenyl-5-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)-9-substituted 5,7-dihydropyrimido[5,4-e][1,2,4]triazolo[4,3-a]pyrimidine-2,4(1H,3H)-dione 26a–c.

molecules-21-01072-sch008_Scheme 8Scheme 8 Synthesis of 5-(3-(furan-2-yl)-1-phenyl-1H-pyrazol-4-yl)-1,3-dimethyl-2,4-dioxo-7-phenyl-9-substituted-1,2,3,4,5,7-hexahydropyrimido[5,4-e][1,2,4]triazolo-[4,3-a]pyrimidines 28a and 28b.

molecules-21-01072-t001_Table 1Table 1 Mean zone of inhibition beyond well diameter (6 mm) produced on a range of clinically pathogenic microorganisms using (5 mg/mL) concentration of tested samples.

Compound	Aspergillus fumigatus (Fungus)	Candida albicans (Fungus)	Streptococcus pneumoniae (Gram +ve Bact.)	Bacillus subtilis (Gram +ve Bact.)	Pseudomonas aeruginosa (Gram −ve Bact.)	Escherichia coli (Gram −ve Bact.)	
9a	0	0	0	0	0	0	
9b	15.7	0	16.2	19.8	0	16.3	
9c	15.6	0	19.6	19.3	0	14.9	
10a	16.3	0	18.9	21.3	0	19.9	
10b	18.8	0	17.3	18.2	0	17.9	
10c	18.6	0	20.6	20	0	15.9	
13b	23.7	25.4	23.8	32.4	17.3	19.9	
13c	14.6	16.9	10.2	9.8	0	11.2	
13f	13.6	11.7	15.6	15.3	0	9.4	
14a	15.9	15.1	17.3	13.3	11.9	11.6	
14b	25.3	17.6	22.6	33.7	13.1	19.3	
14c	10.3	11.3	8.3	10.9	0	8.8	
14e	15.6	12.5	17.3	13.3	10.3	10.9	
14f	0	0	12.6	11.2	0	9.6	
15a	16.9	18.3	17.3	13.4	15.1	13.2	
15b	22.3	16.5	19.5	30.8	12.3	17.6	
15c	20.8	18.9	19.4	14.9	13.6	11.8	
15e	15.4	12.9	19.6	13.9	9.7	8.9	
15f	21.3	17.2	18.2	20.3	0	20.3	
18a	17.1	11.1	13.9	14.2	11.7	10.3	
20	15.4	14.8	10.9	12.9	11.3	11.6	
26a	14.7	10.9	12.2	14.9	11.8	14.7	
26c	13.9	15.6	17.3	20.6	12.5	14.8	
26d	14.9	10.4	21.8	23.3	15.3	19.1	
27	16.2	14.9	15.6	15.6	11.7	10.8	
28a	16.3	13.4	17.5	20.8	0	18.9	
28b	18.6	15.4	13.3	12.7	0	8.5	
Amphotericin B	23.7	25.4	-	-	-	-	
Ampicillin	-	-	23.8	32.4	-	-	
Gentamicin	-	-	-	-	17.3	19.9	
molecules-21-01072-t002_Table 2Table 2 Antimicrobial activity as MICS, (mg/mL) of tested samples against tested microorganisms.

Compound	Aspergillus fumigatus (Fungus)	Candida albicans (Fungus)	Streptococcus pneumoniae (Gram +ve Bact.)	Bacillus subtilis (Gram +ve Bact.)	Pseudomonas aeruginosa (Gram −ve Bact.)	Escherichia coli (Gram −ve Bact.)	
9d	7.81	0	3.9	1.95	0	15.63	
10a	31.25	0	3.9	3.9	0	3.9	
10b	7.81	0	31.25	7.81	0	15.63	
10c	3.9	0	3.9	3.9	0	31.25	
13b	12.5	62.5	3.9	3.9	12.5	15.63	
14b	25	12.5	15.63	7.95	50	31.25	
15f	12.5	62.5	3.9	1.95	25	15.63	
28a	25	50	62.5	62.5	0	25	
Amphotericin B	0.49	0.49	-	-	-	-	
Ampicillin	-	-	0.49	0.24	-	-	
Gentamicin	-	-	-	-	15.63	3.9	
molecules-21-01072-t003_Table 3Table 3 Antimicrobial activity as half maximal inhibitory concentration (IC50) (mg/mL) of tested samples against tested microorganisms.

Compound	Aspergillus fumigatus (Fungus)	Syncephalastrum racemosum (Fungus)	Geotrichum candidum (Fungus)	Candida albicans (Fungus)	Streptococcus pneumoniae (Gram +ve Bact.)	Bacillus subtillis (Gram +ve Bact.)	Pseudomonas aeruginosa (Gram −ve Bact.)	Escherichia coli (Gram −ve Bact.)	
9d	43.21	36.28	18.24	0	17.52	15.63	0	27.34	
10a	64.31	34.28	31.17	0	31.25	18.24	0	31.56	
10b	42.63	33.42	19.63	0	76.34	37.25	0	28.37	
10c	35.24	27.58	24.63	0	25.12	22.41	0	34.25	
Amphotericin B	11.24	16.84	9.32	12.68	-	-	-	-	
Ampicillin	-	-	-	-	10.58	5.29	-	-	
Gentamicin	-	-	-	-	-	-	17.96	16.24
==== Refs
References
1. Shawali A.S.  Abdelhamid A.O.   Synthesis of Spiro-heterocycles via 1,3-Dipolar Cycloadditions of Nitrilimines to Exoheterocyclic Enones. Site-, Regio- and Stereo-Selectivities Curr. Org. Chem. 2012 16 2673 2689 
2. Abdelhamid A.O.  Gomha S.M.  Shawali A.S.   Utility of N -aryl 2-aroylhydrazono propanehydrazonoyl chlorides as precursors for synthesis of new functionalized 1,3,4-thiadiazoles with potential antimicrobial activity J. Adv. Res. 2015 6 885 893 10.1016/j.jare.2014.08.007 26644926 
3. Padmavathi V.  Reddy G.S.  Padmaja A.  Kondaiah P.  Shazia A.   Synthesis, antimicrobial and cytotoxic activities of 1,3,4-oxadiazoles,1,3,4-thiadiazoles and 1,2,4-triazoles Eur. J. Med. Chem. 2009 44 2106 2112 10.1016/j.ejmech.2008.10.012 19036476 
4. Dawood K.M.  Eldebss T.M.A.  El-Zahabi H.S.  Yousef M.H.  Metz P.   Synthesis of some new pyrazole-based 1,3-thiazoles and 1,3,4-thiadiazoles as anticancer agents Eur. J. Med. Chem. 2013 70 740 749 10.1016/j.ejmech.2013.10.042 24231309 
5. Juszczak M.  Matysiak J.  Szeliga M.  Pozarowski P.  Rzeski W.   2-Amino-1,3,4-thiadiazole derivative (FABT) inhibits the extracellular signal-regulated kinase pathway and induces cell cycle arrest in human non-small lung carcinoma cells Bioorg. Med. Chem. Lett. 2012 22 5466 5469 10.1016/j.bmcl.2012.07.036 22877634 
6. Khan I.  Ali S.  Hameed S.  Rama N.H.  Hussain M.T.  Wadood A.  Uddin R.  Ul-Haq Z.  Khan A.  Ali S.    Synthesis, antioxidant activities and urease inhibition of some new 1,2,4-triazole and 1,3,4-thiadiazole derivatives Eur. J. Med. Chem. 2010 45 5200 5207 10.1016/j.ejmech.2010.08.034 20828889 
7. Jubie S.  Ramesh P.N.  Dhanabal P.  Kalirajana R.  Murugananthamb N.  Antonyc A.S.   Synthesis, antidepressant and antimicrobial activities of some novel stearic acid analogues Eur. J. Med. Chem. 2012 54 931 935 10.1016/j.ejmech.2012.06.025 22770606 
8. Dawood K.M.  Abdel-Gawad H.  Ragab E.A.  Ellithey M.  Mohamed H.A.   Synthesis, anticonvulsant, and anti-inflammatory evaluation of some new benzotriazole and benzofuran-based heterocycles Bioorg. Med. Chem. 2006 14 3672 3680 10.1016/j.bmc.2006.01.033 16464601 
9. Harish K.P.  Mohana K.N.  Mallesha L.   Synthesis of indazole substituted-1,3,4-thiadiazoles and their anticonvulsant activity Drug Invent. Today 2013 5 92 99 10.1016/j.dit.2013.06.002 
10. Hasui T.  Matsunaga N.  Ora T.  Nishigaki N.  Imura Y.  Igata Y.  Matsui H.  Motoyaji T.  Tanaka T.  Habuka N.    Identification of Benzoxazin-3-one Derivatives as Novel, Potent, and Selective Nonsteroidal Mineralocorticoid Receptor Antagonists J. Med. Chem. 2011 54 8616 8631 10.1021/jm2011645 22074142 
11. Skrzypek A.  Matysiak J.  Karpinska M.M.  Niewiadomy A.   Enzyme Inhib Med. Chem. 2013 28 816 823 
12. Skrzypek A.  Matysiak J.  Niewiadomy A.  Bajda M.  Szymanski P.   Synthesis and biological evaluation of 1,3,4-thiadiazole analogues as novel AChE and BuChE inhibitors Eur. J. Med. Chem. 2013 62 311 319 10.1016/j.ejmech.2012.12.060 23376249 
13. Patt W.C.  Hamilton H.W.  Taylor M.D.  Ryan M.J.  Taylor D.G. Jr.  Connolly C.J.C.  Doherty A.M.  Klutchko S.R.  Sircar I.  Steinbaugh B.A.    Structure-activity relationships of a series of 2-amino-4-thiazole containing renin inhibitors J. Med. Chem. 1992 35 2562 2572 10.1021/jm00092a006 1635057 
14. Sharma R.N.  Xavier F.P.  Vasu K.K.  Chaturvedi S.C.  Pancholi S.S.   Synthesis of 4-benzyl-1,3-thiazole derivatives as potential anti-inflammatory agents: An analogue-based drug design approach J. Enzym. Inhib. Med. Chem. 2009 24 890 897 10.1080/14756360802519558 19469712 
15. Jaen J.C.  Wise L.D.  Caprathe B.W.  Tecle H.  Bergmeier S.  Humblet C.C.  Heffner T.G.  Meltzner L.T.  Pugsley T.A.   4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: A novel class of compounds with central dopamine agonist properties J. Med. Chem. 1990 33 311 317 10.1021/jm00163a051 1967314 
16. Tsuji K.  Ishikawa H.   Synthesis and anti-pseudomonal activity of new 2-isocephems with a dihydroxypyridone moiety at C-7 Bioorg. Med. Chem. Lett. 1994 4 1601 1606 10.1016/S0960-894X(01)80574-6 
17. Bell F.W.  Cantrell A.S.  Hogberg M.  Jaskunas S.R.  Johansson N.G.  Jordon C.L.  Kinnick M.D.  Lind P.  Morin J.M. Jr.  Noreen R.    Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs J. Med. Chem. 1995 38 4929 4936 10.1021/jm00025a010 8523406 
18. Ergenc N.  Capan G.  Gunay N.S.  Ozkirimli S.  Gungor M.  Ozbey S.  Kendi E.   Synthesis and hypnotic activity of new 4-thiazolidinone and 2-thioxo-4,5-imidazolidinedione derivatives Arch. Pharm. Pharm. Med. Chem. 1999 332 343 347 10.1002/(SICI)1521-4184(199910)332:10<343::AID-ARDP343>3.0.CO;2-0 
19. Carter J.S.  Kramer S.  Talley J.J.  Penning T.  Collins P.  Graneto M.J.  Seibert K.  Koboldt C.  Masferrer J.  Zweifel B.   Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors Bioorg. Med. Chem. Lett. 1999 9 1171 1174 10.1016/S0960-894X(99)00157-2 10328307 
20. Badorc A.  Bordes M.F.  de Cointet P.  Savi P.  Bernat A.  Lale A.  Petitou M.  Maffrand J.P.  Herbert J.M.   New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: Identification of ethyl 3-[N -[4-[4-amino[(ethoxycarbonyl)imino]methyl]phenyl]-1,3-thiazol-2-yl]-N -[1-(ethoxycarbonyl)methyl]piperid-4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent J. Med. Chem. 1997 40 3393 3401 9341914 
21. Rudolph J.  Theis H.  Hanke R.  Endermann R.  Johannsen L.  Geschke F.U.   seco -Cyclothialidines: New concise synthesis, inhibitory activity toward bacterial and human DNA topoisomerases, and antibacterial properties J. Med. Chem. 2001 44 619 626 10.1021/jm0010623 11170652 
22. Fares M.  Abou-Seri S.M.  Abdel-Aziz H.A.  Abbas S.E.S.  Youssef M.M.  Eladwy R.A.   Synthesis and antitumor activity of pyrido[2,3-d ]pyrimidine and pyrido[2,3-d ][1,2,4]triazolo[4,3-a ]pyrimidine derivatives that induce apoptosis through G(1) cell-cycle arrest Eur. J. Med. Chem. 2014 83 155 166 10.1016/j.ejmech.2014.06.027 24956552 
23. Astakhov A.V.  Chernyshev V.M.   Molecular structure of 3-amino[1,2,4]-triazolo-[4,3-a ]pyrimidin-5-one in various tautomeric forms: Investigation by DFT and QTAIM methods Chem. Heterocycl. Compd. 2014 50 319 326 10.1007/s10593-014-1479-2 
24. Liu X.H.  Sun Z.H.  Yang M.Y.  Tan C.X.  Weng J.Q.  Zhang Y.G.  Ma Y.   Microwave assistant one pot synthesis, crystal structure, antifungal activities and 3D-QSAR of novel 1,2,4-triazolo[4,3-a ]pyridines Chem. Biol. Drug Des. 2014 84 342 347 10.1111/cbdd.12323 24636488 
25. Farghaly T.A.  Hassaneen H.M.E.   Synthesis of pyrido[2,3-d ][1,2,4]triazolo[4,3-a ]pyrimidin-5- ones as potential antimicrobial agents Arch. Pharm. Res. 2013 36 564 572 10.1007/s12272-013-0045-2 23446650 
26. Gomha S.M.   A facile one-pot synthesis of 6,7,8,9-tetrahydrobenzo-[4,5]thieno[2,3-d ]-1,2,4-triazolo[4,5-a ]pyrimidin-5-ones Monatsh. Chem. 2009 140 213 220 10.1007/s00706-008-0060-z 
27. Gomha S.M.  Badrey M.G.   Ecofriendly regioselective one-pot synthesis of chromeno[4,3-d ][1,2,4]triazolo[4,3-a ]pyrimidine Eur. J. Chem. 2013 4 180 184 10.5155/eurjchem.4.2.180-184.767 
28. Abdelhamid A.O.  Sayed I.E.  Hussein M.Z.  Mangoud M.M.   Synthesis and Antimicrobial Activity of Some New 1,3,4-Thiadiazoles and 3-(Furan-2-yl)-5-(3-(furan-2-yl)-4,5-dihydro-1-phenyl-1H -pyrazol-4-yl)-4,5-dihydropyrazole-1-carbothioamide World J. Pharm. Sci. 2016 8 1654 1663 
29. Abdelhamid A.O.  Zohdi H.  Rateb N.   Reactions with hydrazonoyl halides part 21. Reinvestigation of the reactions of hydrazonoyl bromides with 1,1-dicyanothioacetanilide J. Chem. Res. (S) 1999 184 185 10.1039/a807566b 
30. Butler R.N.   Comprehensive Heterocyclic Chemistry Katritzky A.R.  Rees C.W.  Scriven E.F.V.   Pergamon Press New York, NY, USA 1996 Volume 4 621 678 
31. Huisgen R.  Grashey R.  Seidel M.  Knupfer H.  Schmidt R.   1.3-Dipolare additionen, III. Umsetzungen des diphenylnitrilimins mit carbonyl und thiocarbonyl-verbindungen Justus. Liebig’s Ann. Chem. 1962 658 169 180 10.1002/jlac.19626580115 
32. Yadav R.C.  Sharma P.K.  Singh J.   Synthesis and biological activity of 4”-substituted-2-(4’-formyl-3’-phenylpyrazole)-4-phenylthiazole J. Chem. Pharm. Res. 2013 5 78 84 
33. Mosselhi M.A.N.   A convenient synthesis of novelderivatives of pyrido[2,3-d ][1,2,4]triazolo[4,3-a ]pyrimidine-5,6-dione Monatsh Chem. 2002 133 1297 1304 10.1007/s00706-002-0469-8 
34. Smania J.A.  Monache F.D.  Smania E.F.A.  Cuneo R.S.   Antibacterial activity of steroidal compounds isolated from Ganoderma applanatum  (Pers.) Pat. (Aphyllophoromycetideae ) fruit body Int. J. Med. Mushr. 1999 1 325 330 10.1615/IntJMedMushr.v1.i4.40 
35. Turnidge J.D.  Ferraro M.J.  Jorgensen J.H.   Susceptibility tEst Methods: General Considerations American Society of Clinical Microbiology Murray 8th ed. Murray P.R.  Baron E.J.  Jorgensen J.H.  Pfaller M.A.  Yolken R.H.   Manual of Clinical Microbiology Washington, DC, USA 2003 1103 
36. Saini K.R.K.  Choudhary S.A.  Joshi Y.C.  Joshi P.   Solvent free synthesis of chalcones and their antibacterial activities E-J. Chem. 2005 2 224 227 10.1155/2005/294094 
37. Bhuiyan M.M.H.  Hossain M.I.  Mahmud M.M.  Al-Amin M.   Microwave-assisted efficient synthesis of chalcones as probes for antimicrobial activities Chem. J. 2011 1 21 28 
38. Shawali A.S.  Osman A.   Synthesis and reactions of phenylcarbamoyl-arylhydrazidic chlorides Tetrahedron 1971 27 2517 2528 10.1016/S0040-4020(01)90753-7 
39. Shawali A.S.  Abdelhamid A.O.   Reaction of dimethylphenacylsulfonium bromide with N -nitrosoacetarylamides and reactions of the products with nucleophiles Bull. Soc. Chem. Jpn. 1976 49 321 324 10.1246/bcsj.49.321 
40. Eweiss N.F.  Osman A.   Synthesis of heterocycles. Part II. New routes to acetylthiadiazolines and alkylazothiazoles J. Heterocycl. Chem. 1980 17 1713 1717 10.1002/jhet.5570170814 
41. Asiri A.M.  Zayed M.E.M.  Ng S.W.   Ethyl 2-chloro-2-(2-phenylhydrazin-1-ylidene)acetate Acta Cryst. 2011 67 o1962 10.1107/S1600536810032587 21588713 
42. Zheng C.J.  Jiang S.M.  Chen Z.H.  Ye B.J.  Piao H.R.   Synthesis and anti-bacterial activity of some heterocyclic chalcone derivatives bearing thiofuran, furan, and quinoline moieties Arch. Pharm. Chem. Life Sci. 2011 344 689 695 10.1002/ardp.201100005 21887800 
43. Sharma P.K.  Kumar S.  Kumar P.  Kaushik P.  Kaushik D.  Dhingra Y.  Aneja K.R.   Synthesis and biological evaluation of some pyrazolylpyrazolines as anti-inflammatory–antimicrobial agents Eur. J. Med. Chem. 2010 45 2650 2655 10.1016/j.ejmech.2010.01.059 20171763 
44. Rateb N.M.  Zohdi H.F.   Atom-efficient, solvent-free, green synthesis of chalcones by grinding Synth. Commun. 2009 39 2789 2794 10.1080/00397910802664244 
45. Nasr M.N.  Said S.A.   Novel 3,3a,4,5,6,7-hexahydroindazole and arylthiazolylpyrazoline derivatives as anti-inflammatory agents Arch. Pharm. Pharm. Med. Chem. 2003 336 551 559 10.1002/ardp.200300796 14677148 
46. Chimenti F.  Maccioni E.  Secci D.  Bolasco A.  Chimenti P.  Granese A.  Befani O.  Turini P.  Alcaro S.  Ortuso F.    Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H )-pyrazole derivatives J. Med. Chem. 2005 48 7113 7122 10.1021/jm040903t 16279769

